vendredi 25 février 2011
Medicine becoming a data-driven science?
- CAn the electronic medical record ccontain an entire genome?, ACP Internist
GenomeQuest Joins Personalized Medicine Coalition
Westborough, MA, February 24, 2011 - GenomeQuest Inc. announced today that it joined the Personalized Medicine Coalition (PMC), a not-for-profit advocacy and educational coalition that advances the understanding and adoption of personalized medicine. GenomeQuest also announced that it would sponsor the personalized medicine conference at Harvard Medical School. Now in its seventh year, the meeting serves as PMC’s annual conference and brings together leaders from across the personalized medicine field.
"With unsustainable costs and an aging population, our health care system faces major challenges. Personalized medicine can be a major part of the solution -- more precise, genomic-driven medicine will result in better and more cost-effective health care,” said Richard Resnick, CEO of GenomeQuest. “We're proud and pleased to be joining the PMC. They are doing a masterful job of leading the collaboration of the health care industry as we collectively plan, communicate, and implement this more personalized approach to medical care."
"A major challenge to advancing personalized medicine is understanding the clinical utility of large amounts of genomic data. Researchers need to be able to analyze new data and clinicians need to be able to generate medically actionable information from these results,” said Edward Abrahams, President of PMC. “We're excited to welcome GenomeQuest, a leader in sequence data management, to PMC to enhance our collaborative effort to see the implementation of a new medical paradigm.”
This announcement follows earlier news from GenomeQuest on a step forward for personalized medicine in diagnostics reporting: clinical practitioners can now interactively produce and query a patient report for genetic tests spanning over 2000 inherited diseases from a single whole-genome or exome sequence. That full announcement is available here.
Also, today at Molecular Med Tri-Con 2011 at 3:20pm (PST), GenomeQuest and medical experts are participating in an industry panel on "Whole-Genome Diagnostics and its Emerging Significance to the Health Care Industry" that will include a demonstration of this new capability for diagnostics companies. More on that panel, including webex live viewing and replay is available here.
About GenomeQuest
GenomeQuest, the global leader in sequence data management, helps life science organizations realize the full promise of genomics. Over 160 leading health and agriculture companies use GenomeQuest for mission-critical work, including nine of the top ten pharmaceuticals. The core technology of the company is the GQ-Engine—a sequence database engine that is purpose-built for storing, managing, and analyzing sequence data at whole- and multi-genome scale.
Learn more at www.genomequest.com.
###
Contact: Dana Wormer, +1 215.888.0960
"With unsustainable costs and an aging population, our health care system faces major challenges. Personalized medicine can be a major part of the solution -- more precise, genomic-driven medicine will result in better and more cost-effective health care,” said Richard Resnick, CEO of GenomeQuest. “We're proud and pleased to be joining the PMC. They are doing a masterful job of leading the collaboration of the health care industry as we collectively plan, communicate, and implement this more personalized approach to medical care."
"A major challenge to advancing personalized medicine is understanding the clinical utility of large amounts of genomic data. Researchers need to be able to analyze new data and clinicians need to be able to generate medically actionable information from these results,” said Edward Abrahams, President of PMC. “We're excited to welcome GenomeQuest, a leader in sequence data management, to PMC to enhance our collaborative effort to see the implementation of a new medical paradigm.”
This announcement follows earlier news from GenomeQuest on a step forward for personalized medicine in diagnostics reporting: clinical practitioners can now interactively produce and query a patient report for genetic tests spanning over 2000 inherited diseases from a single whole-genome or exome sequence. That full announcement is available here.
Also, today at Molecular Med Tri-Con 2011 at 3:20pm (PST), GenomeQuest and medical experts are participating in an industry panel on "Whole-Genome Diagnostics and its Emerging Significance to the Health Care Industry" that will include a demonstration of this new capability for diagnostics companies. More on that panel, including webex live viewing and replay is available here.
About GenomeQuest
GenomeQuest, the global leader in sequence data management, helps life science organizations realize the full promise of genomics. Over 160 leading health and agriculture companies use GenomeQuest for mission-critical work, including nine of the top ten pharmaceuticals. The core technology of the company is the GQ-Engine—a sequence database engine that is purpose-built for storing, managing, and analyzing sequence data at whole- and multi-genome scale.
Learn more at www.genomequest.com.
###
Contact: Dana Wormer, +1 215.888.0960
2,227 genes highly predictive & medically actionable.
@EricTopol at @LIFECorporation: 2,227 genes highly predictive & medically actionable.
A Big And Dangerous Day For Personalized Medicine
References
- A Big And Dangerous Day For Personalized Medicine, Matthew Harper, Forbes, Feb. 23 2011
- Why Matthew Herper has it wrong, prospectivehealth.blogspot.com, Wednesday, February 23, 2011
- Vertex May Make History With Cystic Fibrosis Drug, Forbes, Feb. 23 2011
- Life Tech Pushes Speed Of Small, Fast DNA Sequencer, Forbes, Feb. 23 2011
- Rare Disease Drugs: A $1 Trillion Market?, Forbes, Nov. 19 2010
- A Big And Dangerous Day For Personalized Medicine, Matthew Harper, Forbes, Feb. 23 2011
- Why Matthew Herper has it wrong, prospectivehealth.blogspot.com, Wednesday, February 23, 2011
- Vertex May Make History With Cystic Fibrosis Drug, Forbes, Feb. 23 2011
- Life Tech Pushes Speed Of Small, Fast DNA Sequencer, Forbes, Feb. 23 2011
- Rare Disease Drugs: A $1 Trillion Market?, Forbes, Nov. 19 2010
Inscription à :
Articles (Atom)